B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is preceded by a clinically silent preleukemia. Experimental models that authentically re-capitulate disease initiation and progression in human cells are lacking. We previously described activating mutations in interleukin 7 receptor alpha (IL7RA) that are associated with the poor-prognosis Philadelphialike (Ph-like) subtype of BCP-ALL. Whether IL7RA signaling has a role in initiation of human BCP-ALL is unknown. IL7RA is essential for mouse B-cell development; however, patients with truncating IL7RA germline mutations develop normal mature B-cell populations. Herein, we explore the consequences of aberrant IL7RA signaling activation in human hematopoietic progenitors on malignant B-cell development. Transplantation of human cord-blood hematopoietic progenitors transduced with activated mutant IL7RA into NOD/LtSz-scid IL2Rγ null mice resulted in B-cell differentiation arrest with aberrant expression of CD34 + and persistence of pro-B cells that survive despite failing to achieve productive rearrangement of immunoglobulin V(D)J gene segments. Activation of IL7RA signaling enhanced self-renewal and facilitated the development of a BCP-ALL in secondary transplanted mice. The development of leukemia was associated with spontaneous acquired deletions in CDKN2A/B and IKZF1 similar to what is observed in Ph-like BCP-ALL in humans. Single cell gene expression analysis suggested that pre-leukemic cells resided within a subpopulation of early B-cell precursors with CD34 + CD10 high CD19 low immunophenotype. The development of a bona fide BCP-ALL from IL7RA transduced cells supports the hypothesis that aberrant activation of the IL7RA pathway in human B-cell lineage progenitors has an instructive role by creating a pre-leukemic state which is vulnerable to transformation. These are the first demonstrations of a role for IL7RA in human B-cell differentiation and of a de-novo Phlike BCP-ALL development from normal human hematopoietic progenitors in vivo.
Abstract:
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is preceded by a clinically silent preleukemia. Experimental models that authentically re-capitulate disease initiation and progression in human cells are lacking. We previously described activating mutations in interleukin 7 receptor alpha (IL7RA) that are associated with the poor-prognosis Philadelphialike (Ph-like) subtype of BCP-ALL. Whether IL7RA signaling has a role in initiation of human BCP-ALL is unknown. 
Introduction:
The current paradigm of the evolution of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) suggests two distinct stages: A commonly occurring initiating genetic event that generates pre-leukemia and a rare progression to leukemia through the acquisition of additional somatic genetic events 1 . In childhood ALL the initiating event occurs most commonly in-utero and consists usually of an aberration of a transcriptional regulator. Progression to leukemia is caused by a series of acquired genetic aberrations that halt B-cell differentiation and increase cell proliferation, survival and self-renewal 2, 3 . Increased signaling through RAS or STAT5 pathways are typical progression events and are generally thought to act as the "fuel" enhancing leukemic cell growth [4] [5] [6] [7] . However, activation of signaling may also initiate BCP-ALL, as in the case of BCR-ABL1 translocation, that is generally perceived as a leukemia-initiating event. Yet, this assumption has never been proven experimentally in human hematopoietic progenitor cells.
Interleukin-7 receptor alpha (IL7RA) is a receptor subunit with dual roles. Upon association with Interleukin-2 receptor gamma (IL2Rγ) subunit, it forms the Interleukin-7 (IL7) receptor and when bound to cytokine receptor-like factor 2 (CRLF2) subunit it constitutes the thymic stromal lymphopoietin (TSLP) receptor. Loss-of-function mutations in IL7RA are associated with absent B and T-cells in mice but with the absence of only T-cells in humans 8, 9 . Thus, while IL7RA is important for mouse T and B lymphopoiesis its role in human B-cell development is unclear [10] [11] [12] .
Activation of IL7RA pathway is commonly associated with T-cell malignancies 13 . We previously described IL7RA activating mutations in Philadelphia-like (Ph-like) BCP-ALL 14 .
"Ph-like" leukemia is a subgroup of BCP-ALLs that are associated with poor prognosis and characterized by a similar gene expression signature to BCR-ABL1 ALL [15] [16] [17] . The majority of these leukemias are characterized by aberrant activation of the TSLP receptor and the downstream JAK/STAT signaling pathway 18 . Genomic studies have provided conflicting evidence regarding the role of CRLF2/IL7RA aberrations in leukemic evolution. Aberrant expression of the receptors may be clonal or subclonal, preserved or altered between diagnosis and relapse 7, [19] [20] [21] . Two mouse models suggest that under specific conditions, expression of CRLF2 and/or IL7RA may initiate BCP-ALL [22] [23] [24] . Nevertheless, the relevance of these models to human BCP-ALL is unclear, due to major differences in the role of both IL7 and TSLP signaling in B-cell development in humans. Hence, the role of CRLF2/IL7RA in human leukemia initiation, if any, is unknown.
Here we provide the first experimental evidence in human hematopoietic cells that expression of activated IL7RA (IL7RAins), with or without CRLF2 has an instructive role in human B-cell development by initiating a pre-leukemic state that is vulnerable to evolve to overt "Ph-like" BCP-ALL.
Methods

For detailed methodology see supplementary material
Human CD34 + hematopoietic progenitors
Fresh cord blood (CB) units were obtained from Sheba Medical Center CB bank under Institutional Review Board-approved protocols to obtain CB units for research purposes (Approval 5638-08-SMC, anonymized units that are otherwise discarded due insufficient volume for public storage). CD34 + cells were isolated using magnetic beads (Miltenyi USA) following conventional method.
IL7RA and CRLF2 overexpression
Cloning of IL7RA and CRLF2 into B-cell specific lentiviral vectors (Kindly provided by Rawlings lab 25 ) was performed with standard cloning protocols (see supplementary material). Production of lentiviral vectors was done as previously described 26 , and used to transduce CD34 + hematopoietic progenitors.
Xenotransplants
NOD/LtSz-scid IL2Rγnull (NSG) mice were purchased from Jackson laboratories (Mount Desert Island, Maine, USA). Mice were bred and housed in specific pathogen-free conditions. All animal experiments were approved by the Animal Care Committee at Sheba Medical Center (IRB 1007/15). 5-8-week-old NSG females were irradiated (1-1.5 Gy X-ray) 4-24 hours prior to transplantation. For primary transplantations, 1x10 5 -1.5x10 5 cells were transduced 72-96 hours prior to transplantation. On transplantation days cells were sampled to assess transduction efficiency and transplanted via tail vain injection. 23-30 weeks post transplantation, mice were euthanized and hematopoietic tissues (spleen, bone marrow from femurs, liver and peripheral blood) were harvested.
Flow cytometric analysis
Cells were stained with fluorochrome-conjugated antibodies using standard staining and analysis protocols. Data analysis was done using Kaluza software (Beckman-Coulter, California, USA)
RNA/DNA sequencing and expression profile analysis
Bulk RNA sequencing: RNA was purified from 5000-20000 transduced CD45 + CD3cells that were sorted from spleens of transplanted mice (see details in supplementary methods).
cDNA libraries were prepared using SMARTer kit (Clontech Laboratories, Inc. A Takara Bio Company, Mountain View, CA, USA) followed by the Nextera protocols (Illumina, CA, USA).
Genome-wide expression profiles were obtained by sequencing of the samples on Illumina
NextSeq 500 using NextSeq 500/550 High Output v2 kit. 
Whole genome sequencing
Leukemic and BB transduced corresponding CB cells were collected from transplanted mice.
Sequencing libraries were prepared using NEBNext ULTRA II library preparation kit (see details in supplementary methods) and sequenced on HiseqXten (BGI Hong Kong).
Statistical analysis
Data was analyzed using Microsoft Excel and GraphPad Prism software (La Jolla, CA). Data is either depicted as mean ± SE or as a scatter plot with mean ± SE. Comparisons between groups were performed by unpaired student t-tests in two groups analysis, by one-way ANOVA tests when more than two groups were compared and groups had equal variance or in Kruskal-Wallis-test -a one-way non-parametric analysis of variance, when no equal variance could be assumed. Post hoc analyses were done either by using Dunnett post hoc analysis -to compare samples to control group or by Dunn's/Tukeys multiple comparison test to compare between all experimental groups. P values < 0.05 were considered statistically significant.
Results:
Activation of IL7RA pathway blocks differentiation of human B-cells at the progenitor stage in-vivo
To test the role of activated IL7RA in leukemia initiation we expressed wild type and/or an activated mutant form of human IL7RA containing an in-frame insertion PPCL (Ins12 During normal B-cell differentiation, cells carrying non-productive V(D)J rearrangements undergo programmed cell death 29, 30 . In contrast, acute lymphoblastic leukemia cells often carry non-productive V(D)J rearrangements 31 . We observed a substantial increase in the ratio of the non-productive rearranged fraction in the CRLF2-IL7RAins transduced cells (figure1F). This observation suggests that activation of TSLP/IL7RA signaling provided an enhanced survival capacity of the cells that otherwise would have been destined to programmed death in the absence of productive B-cell receptor rearrangements.
Gene expression analysis of CRLF2/IL7RA activated xenografted cells reveals activation of JAK-STAT, mTOR and survival pathways.
To decipher the mechanism underlying the observed B-cell phenotypic changes we compared the gene expression profile of CRLF2-IL7RAins transduced human cells to that of BB transduced controls from the spleens of primary engrafted mice. As expected, CRLF2 and IL7RA were ranked high in the list of differentially expressed genes confirming successful transduction (supplementary table 1 ). As can be anticipated after activation of the CRLF2/IL7RA signaling 32 This population was enriched with CD34 + cells and can either represent an expanded early-B population or a distinct "pre-leukemic" population.
One of the hallmarks of leukemic cells is the capability of self-renewal, a property of stem cells.
To test whether expression of activated-IL7RA affects self-renewal we re-transplanted 100,000-150,000 transduced cells that were harvested from the BM of primary mice 28-32 weeks after transplantation. As portrayed in figure 3C , the capacity of IL7RA transduced cells harvested from primary mice to repopulate secondary mice was significantly enhanced when compared to cells from mice that were transplanted with BB transduced control. This was particularly evident in the activated-IL7RAins transduced group (p=0.0073, one-way ANOVA test).
Initiation of de-novo leukemia after serial transplantation of activated-IL7RA hematopoietic progenitors
BCP-ALL is the end-result of sequential cumulative mutational events in which an initiation mutation causing "pre-leukemia" is followed by secondary mutations mediating progression to overt malignancy 3 Of note, repertoire sequencing of CD45 + CD19 + CD10 + cells from the primary mouse that generated the leukemia detected the leukemic clone at a frequency of 0.08%-0.02% of the CD10 high CD19 low and CD10 med CD19 + populations respectively (supplementary figure 7) . Thus, the leukemia was derived from a pre-leukemic clone in the primary transplanted mouse.
Karyotypic analysis and Cytoscan HD DNA array of the leukemic cells revealed several DNA copy number abnormalities ( figure 4D and supplementary figure 8 ). Of special interest is the deletion in 9p13 that involves CDKN2A and PAX5 both of which are well characterized progression events in the evolution of BCP-ALL 36 . Genomic analysis also detected an internal IKZF1 deletion (supplementary figure 9 ), another typical progression event in high risk Philadelphia and Ph-like BCP-ALL [37] [38] [39] . Importantly, none of these abnormalities were detected in cells from the same CB transduced with the control backbone vector, confirming that they did not exist in the germline prior to the transduction with activated-IL7RAins receptor ( figure 4D and supplementary figure 9 ). The co-existence of PAX5, CDKN2A and IKZF1 mutations classifies this leukemia as "Ikaros plus" high risk ALL 40 with what was previously reported for ETV6-RUNX1 human ALL 42 .
Leukemia developed only in one CB out of 13 batches of CB that were transduced with IL7RAins vector. Recent gene wide association (GWAS) studies have described several germline single nucleotide polymorphic (SNP) alleles thought to predispose to BCP-ALL [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] .
Interestingly the original CB from which the overt leukemia was developed, carried five germline heterozygous risk SNPs in four genes. Of most interest are the GATA3 SNP (rs3824662)
which was reported to closely associates with Ph-like B-ALL 45, 47, 52 and the CEBPE SNP previously predicted to reduce Ikaros binding to the CEBPE promoter and thus allow for elevated expression of CEBPE 49 (rs2239635). Additional SNPs were detected in ARID5B locus (rs7089424 43 and rs10821936 48, 51 ), and CDKN2BAS locus rs564398 46 (supplementary table 4 ).
Although each of these alleles is relatively common the co-occurrence of five heterozygous
SNPs is remarkable and, like humans, could potentially explain the propensity to transformation.
Single cell analysis of B-cell precursor cells transduced with activated-IL7RA reveals a pre-leukemic population with a strong Ph-like gene signature.
To better characterize the genetic changes that preceded full leukemic transformation we aimed to identify distinctive expression patterns unique for the leukemic and pre-leukemic cells. We hence sorted human CD10 + CD19 + cells from the BM of the leukemic mouse, the pre-leukemic mouse ("pre-leukemia CD10 + CD19 + ") and the mouse engrafted with matching CB transduced with control BB virus. Additionally, we separately sorted the CD10 high CD19 low sub-population presumably enriched with pre-leukemic cells because of their high resemblance to the leukemic immunophenotype ("pre-leukemia CD10 high "). Cells were subjected to 10X single cell gene expression analysis (see experiment illustration figure 5A) .
T-distributed somatic neighbor embedding (TSNE) plot demonstrated a clear separation
between three cell populations: the leukemic cells, the BB control cells and the pre-leukemic CD10 high cells ( figure 5B) . The total CD10 + CD19 + population of the pre-leukemic mouse was distributed between the CD10 high cluster and the BB control cluster.
Bulk differential expression analysis of the above populations shows a close hierarchical relationship between the total CD10 + CD19 + from the pre-leukemic cells and the control backbone transduced cells (only 71 differentially expressed genes-supplementary figure 11A ).
In contrast, comparison of the leukemic cells and the CD10 high pre-leukemic cells to the BB transduced cells revealed 343 and 592 differentially expressed genes respectively (supplementary figure 11A ). 166 of these differentially expressed genes were shared between the leukemia and pre-leukemia CD10 high groups, thus supporting the hypothesis that the CD10 high CD19 low compartment is enriched with "pre-leukemic" cells.
Strikingly, CDKN2A expression which was significantly up-regulated in the IL7RA activated preleukemic CD10 high cluster (as was also in the bulk RNAseq analysis of CRLF2-IL7RAins -see supplementary table 1) was absent in the leukemic cluster (figure 5C) in which CDKN2A was deleted ( figure 4D) . This observation strongly implies that the loss of the negative cell cycle regulator CDKN2A may be important in the leukemic evolution of IL7Rains pre-leukemic cells.
Similar to CRLF2-IL7RAins driven RAG1/2 over expression observed in the bulk RNAseq data (supplementary table 1), elevated levels of RAG1 transcript were detected both in the preleukemic and in the leukemic populations (supplementary figure 11B) . we speculate that similar to what was recently described during V(D)J recombination 53 and specifically reported for ETV6-RUNX1 ALL 42 , increased RAG1/2 activity in B-cell precursor pre-leukemia might lead to genetic instability.
To investigate how closely the experimental leukemia recapitulated primary human Ph-like ALLs, we compiled ranked lists of the differentially expressed genes between the leukemia and the pre-leukemia CD10 high cells and control BB cells and used it in a gene set enrichment analysis against list of differentially expressed genes from two groups of BCP-ALL: Philadelphia and Ph-like BCP-ALL versus combined groups of BCP-ALL leukemias (patient database St.
Jude's group-GSE26281). As seen in figure 5D , a Philadelphia-like gene signature was found both in the leukemic and pre-leukemic sample when compared to the BB control (see major genes contributing to enrichment in supplementary table 5). Similar results were obtained from analysis of bulk RNAseq of CRLF2-IL7RAins vs BB transduced transplanted cells ( figure 5D) .
Furthermore, to test the clinical relevance of our experimental model we assessed the expression of 15 genes that are clinically used in diagnosis of Ph-Like patients 54 . Strikingly, 12
genes from this list out of 13 that were detected in the RNAseq analysis, were predominantly expressed in the pre-leukemic CD10 high and in the leukemic cells whereas only one (PON2), did not show preferential expression pattern ( figure 5E ).
Discussion:
Childhood ALL is preceded by a clinically silent phase of pre-leukemia detectable only through molecular genomic approaches. While the pre-leukemia state is estimated to be fairly common Whether IL7RA signaling has an instructive role in initiation of human BCP-ALL and if so how is the receptor activation driven pre-leukemia is predisposed to transformation, is unknown.
Here we provide the first experimental evidence in human hematopoietic cells, that expression of activated-IL7RA (IL7RAins), with or without CRLF2, modify human B-cell development into a state that could evolve to overt "Ph-like" BCP-ALL.
This "pre-leukemic" compartment of B-cell progenitors is enriched in early B-cell precursors with typical immunophenotype of BCP-ALL (CD34 + CD10 + CD19 + ). These cells carried an increased frequency of loci with only DJ and/or non-productive V(D)J rearrangements of the IgH chain.
The survival of these cells, normally subject to apoptosis due to lack of antigenic selection, might be explained by the increased expression of BCL2L1, previously described to rescue pro-B cells with aberrant V(D)J rearrangements from apoptosis 56 . The expression of other BCL2 family members and pro-survival genes was also increased. Molecularly, these cells displayed the typical "Ph-like" leukemia gene expression signature and, interestingly, increased expression of the cell cycle inhibitor CDKN2A, possibly acting as a "gatekeeper" in restraining aberrant proliferation. This regulator was subsequently lost when these cells further evolved towards overt leukemia. We also observed significantly elevated expression of RAG1/2 in the transduced cells (supplementary table 1 and supplementary figure 11 ). This is not unexpected for B-cells that are held in an early progenitor stage and leads us to speculate that genetic instability driven by prolonged RAG activity might, as previously demonstrated 42, 53, 57 The singularity of the leukemic event may not be surprising since rare secondary spontaneous genomic events are pre-requisite for progression of human pre-leukemia to leukemia. It has been estimated that leukemia develops in only 1% or less of children born with pre-leukemic clones 1, 55, 63, 64 . The time in children for development of leukemia is between 2-15 years while our experiment lasted only up to a year. Interestingly in children the CRLF2/IL7RA subtype occurs later than the other genotypic subtypes of ALL 65 . Recently, gene-wide association studies have discovered several relatively common SNPs conferring a higher risk for childhood ALL 45, 47, 52, [66] [67] [68] . Strikingly, the genotype of the specific CB the transduction of which resulted in BCP-ALL, revealed heterozygosity for five predisposing SNPs scattered across four of these genes. One is GATA3 which has previously been implicated in increased risk of Ph-like ALL 47, 52, 69 . Thus, the leukemia may have arisen in a CB ("a donor") with a higher pre-disposition for BCP-ALL.
We designed this study to elucidate the role of the TSLP and IL7RA receptor pathway activation in the development of BCP-ALL. CRLF2 and IL7RA sequence and function differ between mouse and human [70] [71] [72] [73] [74] [75] . Hence, in this work we studied human cells. The inability of sole expression of CRLF2 to produce a marked phenotype may be explained by the lack of cross reactivity of mouse Tslp with the human CRLF2 receptor as was demonstrated by Payne et al. 76 The most common paired mutation with CRLF2 in BCP-ALL is activated JAK2R683 32, 77 .
However, enforced expression of CRLF2-JAK2R683G in our experimental system was highly toxic to the transduced cells most likely due to hyper-activation of the JAK-STAT signaling pathway as we and others have described 7, 78, 79 . Activating mutations in IL7RA were identified by us and others in both BCP and T ALLs 13, 15, 80, 81 . The most common mutations consist of inframe insertion of cysteine (e.g the in-frame insertion PPCL used in this study) into the extracellular domain causing homodimerization of IL7RA, ligand independent activation and signaling through JAK1-STAT5. Thus, the model generated in our research is highly relevant to human leukemias. To properly study the role of human CRLF2, a mouse strain transgenic for human TSLP is currently being generated.
In summary, we demonstrate here that activation of IL7RA has an instructive role in the development of human B-cell precursor leukemia. It initiates a pre-leukemic state that can evolve to leukemia that recapitulates the natural Ph-like leukemia. As approaches for targeting the CRLF2 and/or IL7RA are currently under development these observations may bear therapeutic significance. 
